Pfizer Inc
PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Aug 4, 2026Score 11/3053% above fair value
$30.67+0.15 (+0.49%)
Close on Nov 2, 2026Market cap $174.81BP/E 40.4Yield 5.61%
Pfizer Elrexfio (elranatamab by Quarter
Elrexfio (elranatamab — BCMA bispecific for multiple myeloma) — Worldwide reported YoY (%) (%)
Pfizer Elrexfio (elranatamab: 4.0% in Q2 2026.
Latest, Q2 2026
4.0%
Period ended Jun 28, 2026
Change on a year earlier
–
History
3 quarters
Since Q4 2025
Sources
3
Documents cited below
Where the Q2 2026 figure comes from
“|| Elrexfio | 89 | 85 | 4% | 5% | 30 | 35 | (15%) | 59 | 50 | 17% | 18%”
Source: Form 8-K (Earnings / Guidance Release) (pfe-6282026xex99.htm, filed 2026-08-04) ↗
Reported in Form 8-K Revenue Tables.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Elrexfio (elranatamab — BCMA bispecific for multiple myeloma) — Worldwide reported YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 28, 2026 | 4.0% | – | Form 8-K (Earnings / Guidance Release) (pfe-6282026xex99.htm, filed 2026-08-04) ↗ |
| Q1 2026 | Mar 29, 2026 | 34.0% | – | Form 8-K (Earnings / Guidance Release) (pfe-3292026xex99.htm, filed 2026-05-05) ↗ |
| Q4 2025 | Dec 31, 2025 | 30.0% | – | Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗ |
Cite this data
StockData. (2026). Pfizer Elrexfio (elranatamab (%), quarterly Q4 2025–Q2 2026 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/elrexfio-yoy-ww
See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.